Results 111 to 120 of about 1,178,585 (315)
MANP in Hypertension With Metabolic Syndrome
Summary: Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome.
Xiao Ma, PhD +11 more
doaj +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source
Portopulmonary hypertension practice patterns after liver transplantation
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose +3 more
wiley +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Diabetes markedly increases susceptibility to adverse cardiovascular events, including heart failure (HF), leading to heightened morbidity and mortality rates.
Dipti Tiwari, Tar Choon Aw
doaj +1 more source
Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani +11 more
wiley +1 more source
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction
Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner +10 more
wiley +1 more source
Background: Hypertension is an increasingly important medical and public health issue. Individualsprone to the development of hypertension often have a hyperdynamic circulation antedating theonset of hypertension by several years.
Meh Jabeen +2 more
doaj
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source

